Fancai Lai

Dr. Fancai Lai

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in Experimental Cell Research
Verified
Journal Article
Closed access
MQMingliang Qiu
Mingliang Qiu
GLGuoping Li
Guoping Li
PWPengcheng Wang
Pengcheng Wang
XLXu Li
Xu Li
FLFancai Lai
Fancai Lai
FLFan-Cai Lai
Fan-Cai Lai

14 May 2024 in Respiratory Research
Verified
Journal Article
Open access
PDF file
LZLiangyu Zhang
Liangyu Zhang
XZXun Zhang
Xun Zhang
MGMaohao Guan
Maohao Guan
JZJianshen Zeng
Jianshen Zeng
FYFengqiang Yu
Fengqiang Yu
FLFancai Lai
Fancai Lai
Background: Previous studies have largely neglected the role of sulfur metabolism in LUAD, and no study has combine iron, copper, and sulfur-metabolism associated genes together to create prognostic signatures. Methods: This study encompasses 1564 LUAD patients, 1249 NSCLC patients, and over 10,000 patients with various cancer types from diverse cohorts. We employed the R package ConsensusClusterPlus to separate patients into different ICSM (Iron, Copper, and Sulfur-Metabolism) subtypes. Various machine-learning methods were utilized to develop the ICSMI. Enrichment analyses were conducted using ClusterProfiler and GSVA, while IOBR quantified immune cell infiltration. GISTIC2.0 and maftools were utilized for CNV and SNV data analysis. The Oncopredict package predicted drug information based on GDSC1. TIDE algorithm and cohorts GSE91061 and IMvigor210 evaluated patient response to immunotherapy. Single-cell data was processed using the Seurat package, AUCell package calculated cells geneset activity scores, and the Scissor algorithm identified ICSMI-associated cells. In vitro experiments was conducted to explore the role of ICSMRGs in LUAD. Results: Unsupervised clustering identified two distinct ICSM subtypes of LUAD, each with unique clinical characteristics. The ICSMI, comprising 10 genes, was constructed using integrated machine-learning methods. Its prognostic power was validated in 10 independent datasets, revealing that LUAD patients with higher ICSMI levels had poorer prognoses. Furthermore, ICSMI demonstrated superior predictive abilities compared to 102 previously published signatures. A nomogram incorporating ICSMI and clinical features exhibited high predictive performance. ICSMI positively correlated with patients gene mutations, and integrated analysis of bulk and single-cell transcriptome data revealed its association with TME modulators. Cells representing the high-ICSMI phenotype exhibited more malignant features. LUAD patients with high ICSMI levels exhibited sensitivity to chemotherapy and targeted therapy but displayed resistance to immunotherapy. In a comprehensive analysis across various cancers, ICSMI retained significant prognostic value and emerged as a risk factor for the majority of cancer patients. Conclusions: ICSMI provides critical prognostic insights for LUAD patients, offering valuable insights into the tumor microenvironment and predicting treatment responsiveness.

28 October 2021 in Frontiers in Genetics
Verified
Journal Article
Open access
JZJinman Zhuang
Jinman Zhuang
MGMaohao Guan
Maohao Guan
MLMaolin Liu
Maolin Liu
YLYuhang Liu
Yuhang Liu
SYShuyan Yang
Shuyan Yang
FHFei He
Fei He
Background: Approximately 50% of thymoma patients also show myasthenia gravis (MG), which is an autoimmune disease; however, the pathogenesis of MG-associated thymoma remains elusive. Our aim was to investigate immune-related lncRNA profiles of a set of candidate genes for better understanding of the molecular mechanism underlying the pathogenesis of thymoma with or without MG.Methods: Molecular profiles of thymoma with or without MG were downloaded from The Cancer Genome Atlas, and Pearson’s correlation analysis was performed to identify immune-related lncRNAs. T test was used to examine the differential expression and differential methylation between thymoma patients with or without MG. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses were performed to predict the function of target genes of immune-related lncRNAs.Results: Analyses of the 87 thymoma samples with complete MG information revealed that 205 mRNAs and 56 lncRNAs showed up-regulated expression in thymoma with MG patients, while 458 mRNAs and 84 lncRNAs showed down-regulated expression. The methylation level of three immune-related lncRNAs (AP000787.1, AC004943.1, WT1-AS, FOXG1-AS1) was significantly decreased in thymoma tissues, and the methylation level of these immune-related lncRNAs (WT1-AS: Cor = 0.368, p < 0.001; FOXG1-AS1: Cor = 0.288, p < 0.01; AC004943.1: Cor = -0.236, p < 0.05) correlated with their expression. GO and KEGG pathway analysis revealed that targets of the immune-related lncRNA FOXG1-AS1 were enriched in small GTPase binding and herpes simplex virus 1 infection. Transcription coregulator activity and cell cycle were the most enriched pathways for targets of lncRNA AC004943.1. LncRNA WT1-AS targets were most enriched in actin binding and axon guidance.Conclusion: Our results revealed the immune-related molecular profiling of thymoma with MG and without MG and identified key pathways involved in the underlying molecular mechanism of thymoma-related MG. These findings provide insights for further research of potential markers for thymoma-related MG.

30 July 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
LZLiangyu Zhang
Liangyu Zhang
JZJianshen Zeng
Jianshen Zeng
XZXun Zhang
Xun Zhang
MZMenglong Zhang
Menglong Zhang
YLYilin Lin
Yilin Lin
FLFancai Lai
Fancai Lai
Background: Regulatory B cells (Bregs) are a distinct subset of B cells that play a crucial role in regulating immune responses and maintaining immune tolerance in cancerous environments. However, their function in lung adenocarcinoma (LUAD) remains largely underexplored. This study seeks to investigate the roles of Breg-associated genes in the context of LUAD.Methods: ConsensusClusterPlus package was used to characterize LUAD patients into two clusters. Differentially expressed genes between the two clusters were then used to construct the BREGI using 32 algorithms, including traditional regression, machine learning, deep learning, and 274 different combinations. The training set, TCGA-LUAD, along with SNV and CNV data, was obtained from the TCGA database. Seven external validation sets and one single-cell RNA sequencing set were downloaded from GEO. Data from the TIDE, TCIA, and TIGER websites were curated to assess the effectiveness of immunotherapy.Results: LUAD patients were divided into two clusters based on 27 Breg-related genes. Patients in Cluster C1 exhibited better prognosis, along with higher immune cell infiltration and immune molecule expression levels, displaying characteristics of a “hot immune” phenotype. The BREGI demonstrated robust predictive power for LUAD patient prognosis across various cohorts. Patients with high BREGI were associated with poor prognosis, higher gene mutation frequencies, a “cold immune” phenotype, and potential resistance to immunotherapy.Conclusions: Breg-related genes significantly characterize LUAD patients into distinct clusters, and the BREGI demonstrated strong prognostic value, providing new insights for future research on Bregs.

15 May 2025 in Cancer Medicine
Verified
Journal Article
Open access
ZCZishan Chen
Zishan Chen
SLShiwen Liu
Shiwen Liu
CCChunting Chen
Chunting Chen
JZJinmang Zhuang
Jinmang Zhuang
XXXinying Xu
Xinying Xu
FHFei He
Fei He
Introduction: An upward trend in the incidence of thymic epithelial tumors (TETs) has been reported over the past few decades, but because of its rarity, little is currently known about its epidemiological trends. This study examined temporal trends in the incidence and mortality of TETs in the US and explored these trends in population subgroups while investigating important factors that influence their prognosis.Methods: A retrospective, population‐based study was conducted using nationally representative data from the Surveillance, Epidemiology, and End Results program, and 4979 patients diagnosed with TETs from 2000 to 2020 were evaluated. Associated population data were used to determine age‐adjusted incidence and mortality, and 5‐year TET‐specific mortality (SM). Trends were assessed for the entire cohort, as well as for particular subgroups, including thymoma and thymic carcinoma.Results: From 2000 to 2020, the overall incidence and mortality of TETs were 2.769 and 1.203 per million person‐years, respectively. Both the age‐adjusted incidence and mortality of TETs increased over the study period, with increases occurring across almost all ethnic groups, histological subtypes, and stages. Multivariate analysis revealed that age, World Health Organization histological type (B1, B2, and B3 thymoma and thymic carcinoma), Masaoka–Koga stage (IIB and III/IV), maximum tumor diameter (5–10 and > 10 cm), surgery, and chemotherapy were independently associated with TET‐SM.Conclusions: The incidence and mortality of TETs have steadily increased over time, and these trends might be related to the widespread use of computed tomography for lung cancer screening and the increasing number of TETs found incidentally. The study also identified several important factors independently associated with TET‐SM, suggesting that early diagnosis and surgical intervention are critical to achieving good prognoses.

9 November 2024 in Discover Oncology
Verified
Journal Article
Open access
PDF file
BXBilin Xu
Bilin Xu
LZLiangyu Zhang
Liangyu Zhang
LLLijie Lin
Lijie Lin
YLYanfeng Lin
Yanfeng Lin
FLFancai Lai
Fancai Lai
Background Lung adenocarcinoma (LUAD) represents a significant global health burden, necessitating advanced prognostic tools for improved patient management. RNA modifications (m6A, m1A, m5C, m7G), and disulfidptosis, a novel cell death mechanism, have emerged as promising biomarkers and therapeutic targets in cancer. Methods We systematically compiled disulfidptosis-correlated genes and RNA modification-related genes from existing literature. A novel disulfidptosis-correlated m6A/m1A/m5C/m7G riskscore was computed using integrated machine-learning algorithms. Transcriptomic data from TCGA and GEO databases were downloaded analyzed. Single-cell RNA-sequencing data from the TISCH database was processed using the Seurat package. Genes’ protein–protein interaction network was constructed using the String database. Functional phenotype analysis was performed using GSVA, ClusterProfiler, and IOBR packages. Consensus clustering divided patients into two distinct groups. Drug sensitivity predictions were obtained from the GDSC1 database and predicted using the Oncopredict package. Results The disulfidptosis-correlated m6A/m1A/m5C/m7G risk score effectively stratified LUAD patients into prognostically distinct groups, demonstrating superior predictive accuracy compared to conventional clinical parameters. Patients in different risk groups exhibited significant molecular and clinical differences. Subsequent analyses identified two molecular subtypes associated with RNA modification and disulfidptosis, revealing differences in immune infiltration and prognosis. Functional enrichment analyses highlighted pathways involving RNA modification and disulfidptosis, underscoring their roles in LUAD pathogenesis. Single-cell analysis revealed distinct features between high- and low-risk status cells. Conclusion This study introduces a novel disulfidptosis-correlated m6A/m1A/m5C/m7G risk score as a robust prognostic tool for LUAD, integrating insights from RNA modifications and cell death mechanisms. The risk score enhances prognostic stratification and identifies potential targets for personalized therapeutic strategies in LUAD. This comprehensive approach emphasizes the critical roles of RNA modifications and disulfidptosis in LUAD biology, paving the way for future research and clinical applications aimed at improving patient outcomes.